← 返回

增强型 NK 细胞作为一种有前景的治疗策略,用于靶向和清除儿童患者中的侵袭性 DIPG 肿瘤

英文原题:Supercharged NK Cells as a Promising Therapeutic Strategy to Target and Eliminate Aggressive DIPG Tumors in Pediatric Patients.

查看英文原题

Supercharged NK Cells as a Promising Therapeutic Strategy to Target and Eliminate Aggressive DIPG Tumors in Pediatric Patients.

PubMed 2025/01/01(内容时间) Crit Rev Immunol Q4 · IF 1.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

弥漫性内生性脑桥胶质瘤(DIPG)是儿科患者常见的死亡原因。在本报告中,我们讨论了超能NK(sNK)细胞单独或与其他疗法联合靶向此类侵袭性儿童脑肿瘤的作用,提示sNK细胞单独作为治疗策略在治疗和预防侵袭性儿童脑肿瘤复发中的潜在应用。

展开英文摘要原文

Diffuse intrinsic pontine glioma (DIPG) is the common cause of death in pediatric patients. In this report, we discussed the role of supercharged NK (sNK) cells alone or in combination with other therapies to target such aggressive pediatric brain tumors, suggesting the potential use of sNK cells alone as a therapeutic strategy in treating and preventing the recurrence of aggressive pediatric brain tumors.

论文信息

作者
Jewett A、Kaur K、Gharamanians N
第一作者单位
Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California School of Dentistry, 10833 Le Conte Ave, 90095 Los Angeles, CA, USA; The Jonsson Comprehensive Cancer Center, UCLA School of Dentistry and Medicine, Los Angeles, CA, USA.United States
通讯作者单位
Division of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, University of California School of Dentistry, Los Angeles, CA 90095, USA.United States
文献类型
综述
期刊
Critical reviews in immunology2025
原文标识
PubMed 40743762 · DOI 10.1615/CritRevImmunol.2025059050